company background image
RLAY logo

Relay Therapeutics NasdaqGM:RLAY Stock Report

Last Price

US$10.29

Market Cap

US$1.3b

7D

-1.8%

1Y

-36.2%

Updated

28 Feb, 2024

Data

Company Financials +

Relay Therapeutics, Inc.

NasdaqGM:RLAY Stock Report

Market Cap: US$1.3b

Relay Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Relay Therapeutics
Historical stock prices
Current Share PriceUS$10.29
52 Week HighUS$19.23
52 Week LowUS$5.95
Beta1.65
1 Month Change3.52%
3 Month Change30.09%
1 Year Change-36.25%
3 Year Change-73.34%
5 Year Changen/a
Change since IPO-70.64%

Recent News & Updates

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Feb 13

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 21
Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Recent updates

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Feb 13

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 21
Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Nov 14
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Jun 08
Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Feb 22
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Oct 23
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts

Sep 30

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Sep 18

Why did Relay Therapeutics stock drop today?

Sep 09

Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 02
Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

Aug 17
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 16
Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business

Mar 26
Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business

Read This Before Selling Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares

Feb 01
Read This Before Selling Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares

Relay Therapeutics inks deal for RLY-1971 with Genentech

Dec 14

Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business

Dec 08
Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business

Relay Therapeutics reports Q3 results

Nov 12

Shareholder Returns

RLAYUS BiotechsUS Market
7D-1.8%4.7%2.1%
1Y-36.2%11.8%26.0%

Return vs Industry: RLAY underperformed the US Biotechs industry which returned 10.7% over the past year.

Return vs Market: RLAY underperformed the US Market which returned 25.1% over the past year.

Price Volatility

Is RLAY's price volatile compared to industry and market?
RLAY volatility
RLAY Average Weekly Movement8.0%
Biotechs Industry Average Movement11.8%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: RLAY has not had significant price volatility in the past 3 months.

Volatility Over Time: RLAY's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015323Sanjiv Patelhttps://www.relaytx.com

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors.

Relay Therapeutics, Inc. Fundamentals Summary

How do Relay Therapeutics's earnings and revenue compare to its market cap?
RLAY fundamental statistics
Market capUS$1.33b
Earnings (TTM)-US$341.97m
Revenue (TTM)US$25.55m

52.8x

P/S Ratio

-3.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RLAY income statement (TTM)
RevenueUS$25.55m
Cost of RevenueUS$326.39m
Gross Profit-US$300.84m
Other ExpensesUS$41.13m
Earnings-US$341.97m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.61
Gross Margin-1,177.64%
Net Profit Margin-1,338.66%
Debt/Equity Ratio0%

How did RLAY perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.